Gain Therapeutics announces formation of clinical advisory board

Gain Therapeutics (GANX) announced the formation of its Clinical Advisory Board, CAB, to support the continued development of the Company’s lead drug candidate, GT-02287, in Parkinson’s disease. The CAB is composed of leading experts in Parkinson’s disease trial design, genetics, and biomarkers and will work closely with Gain leadership to progress GT-02287 through potential Phase 2 and Phase 3 clinical development.